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Background: Platelet-derived growth factors (PDGFs) bind to two receptors, PDGFRα and PDGFRβ to mediate cell
proliferation, migration and survival. Although epithelial cells typically do not express high levels of PDGFRs, their
expression has been reported to increase in breast cancer cells that have undergone epithelial to mesenchymal
transition.
Methods: PDGFR signaling was inhibited using Sunitinib malate, Imatinib mesylate or Regorafenib in murine and
human luminal-like and claudin-low mammary tumor cell lines or Masitinib in only the human cell lines. A scratch
wound assay was used to assess tumor cell migration while immunofluorescence for phosphorylated histone H3 or
cleaved caspase 3 was used to determine tumor cell proliferation and apoptosis, respectively.
Results: Sunitinib and Regorafenib, but not Imatinib, were capable of significantly inhibiting the migration of both
murine and human luminal-like and claudin-low breast cancer cells while Masitinib inhibited migration in both
human breast cancer cell lines. Sunitinib but not Regorafenib or Imatinib also significantly suppressed tumor cell
proliferation in all four cell lines tested while Masitinib had no significant effect on human breast cancer cell proliferation.
None of the PDGFR inhibitors consistently regulated mammary tumor cell apoptosis.
Conclusion: Sunitinib, Regorafenib and Masitinib may prove clinically useful in inhibiting breast cancer cell migration
and metastasis while only Sunitinib (and possibly Regorafenib in some breast cancer subtypes) is effective at inhibiting
both migration and proliferation of breast cancer cells.Introduction
Platelet derived growth factors (PDGFs), as the name
suggests, were originally purified from platelets [1-4].
PDGFs form homodimers consisting of A-, B-, C- and
D-polypeptides or heterodimers consisting of A and B
polypeptides. These ligands induce signaling by bind-
ing to one of two PDGFR receptor isoforms, PDGFRα
and PDGFRβ. PDGFRα binds all members of the PDGF
dimers other than D-polypeptides while PDGFRβ bind
the B- and D-polypeptides [5]. PDGFRs are tyrosine kinase
receptors and ligand binding induces receptor dimerization
and intracellular signaling including activation of PLCγ, Src,
SHP-2, RasGAP, PI3-kinase and STAT proteins [5]. These* Correspondence: rmoorehe@uoguelph.ca
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PDGFRs are typically not expressed in normal epithelial
cells but are expressed in fibroblasts and smooth muscle
cells [6] where these receptors regulate physiologic
processes such as wound healing, inflammation and
angiogenesis [7]. Tumors associated with enhanced PDGFR
signaling include sarcomas, gastrointestinal stromal tumors
and several types of leukemias [8].
With respect to breast cancer, less is known about the
importance of PDGFs or PDGFRs. Studies have shown
that PDGF-D is upregulated in invasive breast cancer
while PDGF-BB is found at higher levels in patients with
breast cancer compared to those with benign breast dis-
ease and the expression PDGFRs is a predictor of poor
prognosis [9-11]. Additionally, more recent research has
found that PDGF signaling is elevated in breast cancer
cells that have become resistant to endocrine therapyLtd. This is an Open Access article distributed under the terms of the Creative
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breast cancer is during epithelial to mesenchymal tran-
sistion (EMT). EMT is a process whereby epithelial cells
acquire a more mesenchymal phenotype and gene ex-
pression profile and EMT has been implicated in more
aggressive/metastatic breast cancers [14-17].
A number of agents capable of inhibiting PDGFR sig-
naling have been developed including Sunitinib malate
(Sutent), BAY 73–4506 (Regorafenib) and Imatinib mesy-
late (Gleevec). Sunitinib malate inhibits PDGFRβ, VEGFR2,
Kit and FLT-3 [18–20]. This agent is currently FDA ap-
proved for the treatment of gastrointestinal stromal tu-
mors, pancreatic neuroendocrine tumors and renal cell
carcinoma and is currently in clinical trials for the treat-
ment of breast cancer (www.cancer.gov). Regorafenib is
FDA approved for the treatment of colorectal cancer
and gastrointestinal stromal tumors (www.cancer.gov).
Regorafenib can bind to and inhibit PDGFRβ as well as
VEGFR2, VEGFR3, Ret, Kit and Raf [21,22]. Imatinib
mesylate is FDA approved for the treatment of acute
lymphoblastic leukemia, chronic eosinophilic leukemia,
chronic myelogenous leukemia, germatofibrosarcoma pro-
tuberans, gastrointestinal stromal tumor, myelodysplastic/
myeloproliferative disorders and systemic mastocytosis.
Imatinib mesylate inhibits PDGFRα/β, c-kit and bcr-abl
(www.cancer.gov). A more recently described inhibitor of
PDGFRα and PDGFRβ is Masitinib. Masitinib inhibits
Kit, PDGFRα, PDGFRβ and Lyn [23]. Masitinib is not
FDA approved for any human cancers but is approved
for use in canine mast cell tumors [24].
We have previously shown that PDGFRs were elevated
in a murine mammary tumor cell line that has mesenchy-
mal characteristics and closely resembles the human
breast cancer subtype, claudin-low [25-27]. Claudin-low
tumors are similar to basal-like breast cancer in that they
are typically estrogen receptor, progesterone receptor and
HER2 negative and express a number of mesenchymal
genes. Claudin-low tumors are differentiated from basal-
like tumors by the higher expression of genes involved
in immune response, cell communication, extracellular
matrix, cell migration and angiogenesis and their lower
expression of claudins 3, 4, 7, and occludin [28,29]. We
also showed previously that knockdown of PDGFRα, or
knockdown of both PDGFRs significantly inhibited mi-
gration but did not inhibit proliferation or promote
apoptosis in our claudin-low murine mammary tumor
cell line [25].
In the current manuscript we extended our previous
work to determine whether inhibitors of PDGFR could
suppress migration and survival of murine and human
luminal and claudin-low mammary tumor cells. We found
that Sunitinib malate and Regorafenib significantly inhib-
ited migration of all 4 cell lines tested. Sunitinib was also
capable of suppressing proliferation in all 4 cell lines whileRegorafenib suppressed proliferation only in the human
claudin-low breast cancer cell line. Imatinib only signifi-
cantly inhibited migration in the human luminal breast
cancer cell line and had no significant effect on prolifera-
tion in any of the cell lines. Masitinib inhibited migration
of both human breast cancer cell lines but had no effect
on proliferation or apoptosis.
Materials and methods
Cells and culture conditions
RJ345 and RJ348 cells were generated in our lab and
have previously been described [30]. RJ345 and RJ348
cells were cultured in DMEM containing 10% FBS,
1 mmol/L sodium pyruvate, 10 mmol/L HEPES, 4 mmol/L
glutamine, 2 mmol/L hydrocortisone, 5 μg/mL estrogen,
5 μg/mL prolactin, 10 μg/mL epidermal growth factor,
10 μg/mL insulin and 1% antibiotic/antimycotic. MCF-7
cells were maintained in α-MEM media containing 10%
FBS and 1% antibiotic/antimycotic while MDA-MB-231
were maintained in RPMI media containing 10% FBS
and 1% antibiotic/antimycotic.
PDGFR inhibitors
Regorafenib (Bay 73–4506), Imatinib mesylate (Gleevec),
Masitinib (AB1010), and Sunitinib malate (Sutent) were
purchased from Selleck Chemicals (Houston TX). All
inhibitors were re-suspended in DMSO.
Scratch wound assay
Cells were plated in 6-well plates in fully supplemented
media such that they were 90-100% confluent at the
time the scratch was performed. Once the scratch was
made the media was removed and replaced with fully
supplemented media containing different concentrations
of Masitinib, Regorafenib, Sunitinib or Imatinib. Images
of the scratch were captured immediately after the scratch
was induced and 24 or 48 hrs after drug administration.
Percentage of the wound closed was calculated using
ImageJ software (NIH). All drugs were diluted such that
each well contained 0.1% DMSO and the control well
contained 0.1% DMSO.
Immunofluorescence
Cells were plated in fully supplemented media on sterile
glass coverslips in 6 well dishes at 20-30% confluence.
Cells were allowed to adhere overnight and then the
medium was removed and replaced with fully supple-
mented media containing Masitinib, Regorafenib, Sunitinib,
or Imatinib. All drugs were diluted such that each well
contained 0.1% DMSO and the control well contained
0.1% DMSO. Twenty-four hours later the media was re-
moved, the cells washed 3 times in ice cold PBS and
then fixed in 10% neutral buffered formalin for 1 hour
at room temperature. Cells were washed 3 times in PBS
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20. For proliferation, cells were incubated with a 1:2000
dilution of an antibody against phospho-histone H3 (S10)
(Abcam Inc, Toronto, ON; cat# ab14955) overnight at 4°C.
For apoptosis, cells were incubated with a 1:500 dilution of
an antibody against cleaved caspase 3 (EMD Millipore,
Billerica, MA; cat# AB3623) overnight at 4°C. The cells
were then washed twice in PBS and incubated with a 1:200
dilution of the appropriate fluorescently labeled secondary
antibody for 1 hour at room temperature. Cells were
washed, counterstained with DAPI and visualized using an
Olympus BX61 fluorescent microscope (Olympus, Center
Valley, PA) using Metamorph imaging software (Molecular
Devices, Sunnyvale, CA). The number of positive cells and
total number of cells were counted from at least 3 inde-
pendent experiments.
Statistics
An ANOVA followed by a Dunnett’s posthoc analysis
was performed to determine statistically significant values.
Values were considered significant when p < 0.05.
Results
We have previously shown that RJ348 cells have charac-
teristics similar to human claudin-low breast cancer while
RJ345 cells resemble human luminal breast cancer [26].
We have also previously shown that RJ348 cells have ele-
vated levels of PDGFRα and PDGFRβ compared to RJ345
cells and RNAi mediated knockdown of PDGFRs inhibited
migration of RJ348 cells [25]. Although useful as a scien-
tific tool, RNAi has limited therapeutic potential. There-
fore, we evaluated the ability of several PDGFR inhibitors
to regulate proliferation, apoptosis and migration in luminal-
like and claudin-low breast cancer cells.
Since the most dramatic effect observed following
PDGFR knockdown in the RJ348 cells was an inhibition of
tumor cell migration [25] , tumor cell migration was eval-
uated using a scratch wound assay and Regorafenib, Suni-
tinib and Imatinib were tested at 100 nM, 500 nM and
5 μM. All of the inhibitors were re-suspended in DMSO
and all dilutions were performed in DMSO such that each
well received the inhibitor and 0.1% DMSO. Control wells
contained 0.1% DMSO. Figure 1A-D shows representative
scratch wounds for RJ348 cells at time 0 (when the scratch
was made) and 24 hours after inducing the wound in cells
treated with DMSO or Sunitinib at 5 uM. The bar graphs
(Figure 1E,F) represent the percent of the wound that
closed 24 hrs after wounding for the RJ348 cells and
48 hrs after wounding for the RJ345, MCF-7 and MDA-
MB-231 cells. The murine claudin-low mammary tumor
cell line, RJ348, migrated more rapidly than the luminal-
like mammary tumor cell line, RJ345. In fact, the RJ348
cells migrated so quickly that the control cells (DMSO)
completely closed the wounds by 48 hrs and thus the24 hr time point was used for these cells. The human
claudin-low cell line, MDA-MB-231, migrated more
quickly than the luminal breast cancer cell line MCF-7
as illustrated by comparing the DMSO controls for the
two cell lines. Regorafenib, Sunitinib and Imatinib failed
to significantly reduce tumor cell migration when admin-
istered at 100 nM (data not shown). Only Sunitinib signifi-
cantly reduced migration at 500 nM and this was only
observed in the RJ348 cells (Figure 1E). At 5 μM, both
Sunitinib and Regorafenib significantly inhibited migra-
tion in all cell lines while Imatinib only inhibited MCF-7
migration (Figure 1F).
Next, cell proliferation in response to 5 μM of each in-
hibitor was evaluated. Figure 2 shows cell proliferation
relative to the DMSO control and it was observed that
5 μM of Sunitinib significantly inhibited cell proliferation
in all 4 cell lines while Regorafenib (5 μM) significantly
inhibited proliferation only in MDA-MB-231 cells. Ima-
tinib (5 μM) did not significantly inhibit proliferation in
any of the cell lines.
When apoptosis was evaluated, only 5 μM of Sunitinib
significantly induced apoptosis and this was only ob-
served in the RJ345 cells. The graph in Figure 3 repre-
sent the percentage of apoptotic cells in each treatment
and as can be seen in the graph, the levels of apoptosis
were very low. The RJ345 cells treated with 5 uM of Su-
nitinib had the highest level of apoptosis and even this
was only observed in approximately 1.8% of the cells.
A more recently identified inhibitor of PDGFRα and
PDGFRβ, Masitinib, was evaluated at 5 μM and 10 μM
in MCF-7 and MDA-MB-231 cells and was found to sig-
nificantly inhibit migration in both MCF-7 and MDA-
MB-231 cells at both 5 μM and 10 μM (Figure 4) but
did not significantly impact proliferation or apoptosis in
either cell line at either concentration (data not shown).
Masitinib was not evaluated in the murine mammary
tumor cell lines.
Discussion
Our previous study showed that murine claudin-low mam-
mary tumor cells expressed elevated levels of PDGFRα and
PDGFRβ compared to murine luminal mammary tumor
cells. In addition, knockdown of PDGFRα or PDGFRβ sig-
nificantly reduced migration but not proliferation of the
claudin-low mammary tumor cells [25]. Although targeting
PDGFRs with RNAi is a useful scientific tool, this approach
is unlikely to be clinically viable. Therefore we examined
the efficacy of several PDGFR small molecule inhibitors in
both our murine mammary tumor cell lines and in human
breast cancer cell lines. The cell lines were chosen such
that there would be one murine luminal-like (RJ345) and
one human luminal cell line (MCF-7) as well as one mur-
ine (RJ348) and one human (MDA-MB-231) claudin-low
cell line. Since a purely selective PDGFR inhibitor does not
Figure 1 (See legend on next page.)
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Figure 1 Sunitinib and Regorafenib inhibit mammary tumor cell migration. A scratch wound assay was performed on RJ345, RJ348, MCF-7
and MDA-MB-231 cells treated with 500 nM or 5 μM of Regorafenib, Sunitinib or Imatinib. (A-D) shows representative scratch wounds from RJ348
cells at time 0 (A,C) and 24 hrs (B,D) after the initiation of the scratch when the cells were treated with the vehicle control, DMSO (A,B), or 5 μM
of Sunitinib (C,D). The red line indicates the initial scratch wound. The percentage of the wound closed was quantified from a minimum of 3
independent replicates and is expressed as mean ± SEM when treated with (E) 500 nM or (F) 5 μM of Regorafenib, Sunitinib or Imatinib. Wounds
were created and inhibitors were added immediately. Wounds were evaluated at 24 hrs after inhibitor administration for the RJ348 cells and
48 hrs for RJ345, MCF-7 and MDA-MB-231 cells. *Indicates values that were significantly different (p < 0.05) from the DMSO control.
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and are currently used clinically. These inhibitors were Re-
gorafenib (Bay 73–4506), Imatinib mesylate (Gleevec) and
Sunitinib malate (Sutent). In addition, Masitinib, which is
not clinically used for human cancers but is used for ca-
nine mast cell tumors [24] was evaluated in the human
breast cancer cell lines. Masitinib was included in the study
as it inhibits PDGFRα and PDGFRβ (similar to Imatinib)
while Regorafenib and Sunitinib only inhibit PDGFRβ.
There were a number of surprising findings in this
study. The first surprising finding was that Regorafenib
and Sunitinib were equally capable of suppressing mam-
mary tumor cell migration and proliferation in both
luminal-like and claudin-low cell types. Based on western
blots from our previous study [25] we anticipated either
(i) the claudin-low tumor cells would be more sensitive to
PDGFR inhibition as these cells express higher levels of
PDGFR and thus were more dependent on PDGFR signal-
ing for migration and proliferation or (ii) the higher levels
of PDFGR found in the claudin-low tumor cells would
render these cells more resistant to PDGFR inhibition as
higher concentrations of Sunitinib or Regorafenib would
be required to competitively block PDGFR signaling. TheFigure 2 Sunitinib inhibits mammary tumor cell proliferation. Cell pro
immunofluorescence. The bar graph represents the mean ± SEM of the pe
(n ≥ 3). *Indicates values that were significantly different (p < 0.05) from thpercentage of migration inhibited was similar in the
luminal-like cell lines compared to their claudin-low
counterparts indicating that PDFGR expression did not
predict sensitivity to PDGFR inhibition. However, it
does appear that both luminal-like and claudin low
breast cancer cells rely on PDGFR signaling for migra-
tion and that PDGFR inhibitors can effectively sup-
press migration even in cells that express high levels of
PDGFRs.
The second surprising finding was that Sunitinib inhib-
ited proliferation of the claudin-low cell lines. At least for
the RJ348 cells, our previous study showed that knock-
down of PDGFR either had no effect on proliferation or
induced a slight increase in proliferation. In the current
study Sunitinib inhibited proliferation of all four cell lines.
This effect is likely results from inhibition of kinases other
than PDGFRβ.
The third surprising finding was that Imatinib was less
effective at inhibiting migration than either Sunitinib
or Regorafenib. Our previous study showed that concomi-
tant knockdown of both PDGFRα and PDGFRβ was the
most effective strategy for inhibiting RJ348 migration and
knockdown of PDGFRα was more effective at suppressingliferation was assessed using phosphorylated histone H3 (S10)
rcentage of positively stained cells relative to the DMSO control
e DMSO control.
Figure 3 Sunitinib promotes apoptosis in RJ345 cells. Cell apoptosis was assessed using cleaved caspase 3 immunofluorescence. The bar
graph represents the mean ± SEM of the percentage of positively stained cells (n ≥ 3). *Indicates values that were significantly different
(p < 0.05) from the DMSO control.
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targets both PDGFRα and PDGFRβ while Sunitinib and
Regorafenib only target PGDFRβ, we anticipated that Ima-
tinib would be the most effective inhibitor at suppressing
tumor cell migration. The lack of effect of Imatinib could
be due to the higher IC50 for PDGFR inhibition (100 nM)
compared to Sunitinib (PDGFRβ IC50 of 2 nM) and Re-
goragenib (PDGFRβ IC50 of 22 nM). It is also possible that
a kinase targeted by both Sunitinib and Regorafenib, but
not Imatinib, is critical for migration and proliferation inFigure 4 Masitinib inhibits migration of MCF-7 and MDA-MB-231 cell
3 independent scratch wound assays and is expressed as mean ± SEM wh
Masitinib was added to the cells immediately after the creation of the wou
*Indicates values that were significantly different (p < 0.05) from the DMSOthe tumor cells tested. However, the fact that Masitinib,
which inhibits both PDGFRα and PDGFRβ as well as c-kit
(similar to Imatinib), significantly inhibited migration of
both human breast cancer cell lines, but had no effect on
proliferation or apoptosis argues against the IC50 or other
kinase targets limiting Imatinib’s efficacy. Masitinib’s IC50
for PDGFRα and PDGFRβ is reported to be higher than
Imatinib’s and the kinases inhibited by Masitinib are also
inhibited by Imatinib. Therefore, it appears that inhibition
of PDGFRβ can suppress breast cancer cell migration buts. The bar graph represents the percentage of the wound closed from
en treated with (grey bar) 5 μM or (black bar) 10 μM of Masitinib.
nd and wounds were evaluated at 48 hrs after inhibitor administration.
control.
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would be consistent with our observations using PDGFR
RNAi in RJ345 and RJ348 cells in that inhibition of
PDGFRs can suppress migration but not proliferation
[25]. The ability of Sunitinib and Regorafenib to inhibit
breast cancer cell proliferation presumably results from
inhibition of a kinase other than PDGFRβ. The only kin-
ase reported to be targeted by both Sunitinib and Rego-
rafenib (that is not targeted by Masitinib) is VEGFR2
and thus this receptor deserves further investigation as
an anti-proliferative agent in the treatment of breast
cancer.
A review of the literature revealed that Regorafenib
has not been tested on MCF-7 or MDA-MB-231 cells
in vitro. One manuscript did evaluated the effects of
Regorafenib on MDA-MB-231 cells in vivo and found
that Regorafenib at 3 mg/kg and higher significantly
inhibited MDA-MB-231 xenograft growth [21]. For
Sunitinib, one manuscript examined MCF-7 and MDA-
MB-231 proliferation in vitro. This study showed that
5 uM of Sunitinib significantly inhibited proliferation of
both MCF-7 and MDA-MB-231 cells as assessed using a
H3-thymidine assay. Migration was not evaluated [31].
Three studies examined the effects of Imatinib on MCF-7
and MDA-MB-231 cells in vitro. One study showed that
the IC50 of Imatinib in both MCF-7 and MDA-MB-231
cells was approximately 7 uM [32]. At 5 μM, Imatinib re-
duced MDA-MB-231 proliferation to approximately 75%
of control and MCF-7 proliferation to approximately 85%
of control [32]. In the second study it was found that ima-
tinib at concentrations of 3 uM and higher could inhibit
proliferation of both MCF-7 and MDA-MB-231, however,
these studies were performed in serum-free conditions
[33]. The final study showed that Imatinib could inhibit
MCF-7 but not MDA-MB-231 cell migration at 48 hrs
after administration of 6 uM of Imatinib when the cells
were cultured in 1% serum [34]. Therefore, our findings
on Regorafenib, Sunitinib and Imatinib are consistent with
the limited number of breast cancer studies using these
agents. No study has evaluated Masitinib treatment on
MCF-7 or MDA-MB-231 cells. Therefore, this is the first
study to demonstrate that Masitinib can inhibit migration
of luminal and claudin-low human breast cancer cells but
has no significant impact on proliferation or apoptosis.
Pharmacokinetic studies in mice and rats have shown
maximal plasma concentrations of Sunitinib that can be
achieved are in the range of 3–3.5 μM [35]. In humans,
administration of more than 50 mg of Sunitinib daily is
associated with significant toxicity and at 50 mg/day,
plasma levels of Sunitinib range from 50–90 ng/ml (~0.1
μM-0.17 μM) [36]. However, a study by Gotink et al.
[37] has shown that intratumoral concentrations of Sunitinib
are more than 10-fold higher than plasma samples. In
mice administered Sunitinib at 40 mg/kg/day, plasmaconcentrations were approximately 1 μM while tumor
concentrations were approximately 11 μM. Similarly in
humans administered 37.5-50 mg of Sunitinib per day,
plasma concentrations were approximately 0.3 μM while
tumor concentrations were approximately 9.5 μM. For
Regorafenib and Imatinib, plasma concentrations of
2522 ng/ml (5.2 μM) and 3000 ng/ml (5.1 μM) respect-
ively, have been reported [38,39]. Plasma concentra-
tions for Masitninb in humans has not been reported
but concentrations of 1886 ng/ml (3.9 μM) have been
reported in cats [40]. Therefore, the concentrations
used in this study are within the range of those clinic-
ally achievable.
Although clinical trials using Sunitinib in the treatment
of breast cancer have been disappointing thus far [41-43]
a recent study from the Weinberg lab reinforces the im-
portance of PDGFR signaling in breast cancer. These in-
vestigators found that that EMT and the enrichment of
breast cancer stem cells was associated with a switch from
EGFR signaling to PDGFR signaling [44]. In addition this
study showed that PDGFR expression was elevated in
mammary tumor cells with stem cell properties and
PDGFR inhibitors could selectively target breast cancer
cells with stem cell properties [44]. Therefore, additional
research is required to identify specific PDGFR inhibitors
and how best to utilize these agents for targeting different
breast cancer subtypes or specific cell types (ie stem cells)
in breast cancers.
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